Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAT5906 versus Lucentis in pathologic myopia-associated choroidal neovascularization
CTR20253383Phase 3Active
- Sponsor
- Bio-Thera Solutions, Ltd.
- Start
- Oct 2025
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of BAT5906, ranibizumab in myopic choroidal neovascularisation (mCNV), sponsored by Bio-Thera Solutions, Ltd.. Started Oct 2025; status: active.
02
Drugs
BAT5906ranibizumab
03
Conditions
myopic choroidal neovascularisation (mCNV)
Beyond the preview
Go deeper on CTR20253383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253383.